RedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018. Post author:jaimeuss_admin Post published:17 בSeptember 2018 Post category:Research Continue ReadingRedHill Biopharma Ltd.: Q3 results did not meet expectations mainly with GI drug sales; financially, capital raising of $20.6M (NIS 1.94 per share) positions Redhill with sufficient funds until 2018.
Energix Renewable Energies Ltd.: Completion of stage II connection to the company’s flagship Polish project and successful capital raising are positive indicators. We have raised the price target to NIS 3.82. Post author:jaimeuss_admin Post published:6 בSeptember 2018 Post category:Research Continue ReadingEnergix Renewable Energies Ltd.: Completion of stage II connection to the company’s flagship Polish project and successful capital raising are positive indicators. We have raised the price target to NIS 3.82.